Our Pricing

Understanding Long-Term Omeprazole Side Effects

Published on: June 03, 2026

Concerns about long-term omeprazole side effects UK patients experience are increasingly common in our consultations at Cured Pharmacy. Omeprazole remains one of the most prescribed proton pump inhibitors (PPIs) in the UK, but extended use beyond the recommended duration may carry specific risks that warrant clinical review. Our superintendent pharmacist Tarun Kumar and the UK clinical team regularly assess whether patients might benefit from dose adjustment, treatment breaks, or alternative acid-reflux therapies.

What Are the Long-Term Omeprazole Side Effects UK Patients Should Monitor?

Omeprazole works by blocking gastric acid production in the stomach lining, providing effective relief from conditions like gastro-oesophageal reflux disease (GORD) and peptic ulcers [1]. However, prolonged suppression of stomach acid—typically defined as continuous use beyond 12 months—can interfere with nutrient absorption and alter gut microbiota.

Clinical evidence shows that extended omeprazole use may increase the risk of vitamin B12 deficiency, magnesium depletion, and reduced calcium absorption, potentially affecting bone density over time [2]. The MHRA has issued guidance recommending regular review of PPI therapy, particularly for patients taking high doses or continuing treatment beyond the initially indicated period.

Common long-term side effects include gastrointestinal changes such as small intestinal bacterial overgrowth (SIBO), increased susceptibility to Clostridium difficile infection, and in rare cases, fundic gland polyps [3]. Patients may also experience rebound acid hypersecretion when attempting to discontinue treatment, which can be mistaken for treatment failure rather than a withdrawal effect.

Bone Health and Fracture Risk with Prolonged PPI Use

One of the most studied long-term omeprazole side effects UK research has focused on is the potential impact on bone mineral density. Chronic acid suppression reduces calcium absorption in the intestine, which may contribute to osteoporosis and increased fracture risk, particularly in the hip, spine, and wrist [2].

A meta-analysis published in the British Medical Journal found that patients using PPIs for more than one year had a modestly elevated risk of osteoporotic fractures compared to non-users, with the risk increasing alongside dose and duration [4]. This effect appears most significant in elderly patients, postmenopausal women, and those with additional risk factors such as smoking or corticosteroid use.

NICE guidance recommends that clinicians consider bone health when prescribing long-term PPIs, particularly advising calcium and vitamin D supplementation where appropriate, and using the lowest effective dose for the shortest necessary duration.

Monitoring Bone Density During Long-Term Treatment

Patients on continuous omeprazole therapy beyond two years should discuss bone density screening with their GP, especially if other risk factors are present. Regular DEXA scans may be recommended to assess bone mineral density and guide preventive interventions such as bisphosphonate therapy or lifestyle modifications including weight-bearing exercise and adequate dietary calcium.

Vitamin and Mineral Deficiencies Associated with Omeprazole

Stomach acid plays a crucial role in liberating vitamins and minerals from food, particularly vitamin B12, magnesium, and iron. Long-term omeprazole use can impair this process, leading to clinically significant deficiencies that may manifest as fatigue, neuropathy, muscle weakness, or anaemia [2][5].

Vitamin B12 deficiency is particularly concerning because it requires gastric acid to separate from dietary proteins before absorption in the small intestine. Studies show that patients taking PPIs for more than two years have a significantly increased risk of B12 deficiency, which can cause irreversible neurological damage if left untreated [5].

Hypomagnesaemia (low magnesium levels) has been reported in patients taking omeprazole for three months or longer, potentially causing muscle spasms, cardiac arrhythmias, and seizures in severe cases. The MHRA recommends checking magnesium levels before starting long-term PPI therapy and periodically during treatment, particularly in patients taking digoxin or diuretics.

When to Request Blood Tests

If you've been taking omeprazole for more than 12 months, consider requesting annual blood tests to monitor vitamin B12, magnesium, and ferritin levels. Early detection of deficiencies allows for timely supplementation and prevents progression to more serious complications such as peripheral neuropathy or cardiac conduction abnormalities.

Kidney Function and Chronic Kidney Disease Risk

Emerging evidence has linked long-term PPI use to an increased risk of acute interstitial nephritis and chronic kidney disease (CKD), though the absolute risk remains relatively low [6]. The mechanism is not fully understood but may involve immune-mediated inflammation of the kidney tissue.

A large cohort study published in JAMA Internal Medicine found that patients using PPIs had a 20-50% higher risk of developing CKD compared to non-users, with risk correlating to duration of use [6]. However, it's important to note that this represents an association rather than definitive causation, and many patients take PPIs safely for years without kidney complications.

The GPhC recommends that pharmacists counsel patients on long-term omeprazole about the importance of staying hydrated, avoiding nephrotoxic medications where possible, and reporting symptoms such as reduced urine output, swelling, or unexplained fatigue to their GP promptly.

Safer Alternatives to Long-Term Omeprazole UK Prescribers Recommend

For patients concerned about prolonged omeprazole use, several alternative approaches may provide effective acid-reflux control with potentially lower long-term risks. At Cured Pharmacy, our clinical team can assess whether switching to a different PPI, reducing to a lower maintenance dose, or trying an H2-receptor antagonist might be appropriate.

Esomeprazole and lansoprazole are alternative PPIs with similar efficacy profiles but different pharmacokinetic properties that some patients tolerate better during dose reduction or intermittent therapy [1]. For mild to moderate GORD, stepping down to an H2-receptor antagonist like famotidine or ranitidine (when available) may maintain symptom control with less profound acid suppression.

Lifestyle modifications remain fundamental to managing acid reflux and may allow dose reduction or treatment breaks. Evidence-based interventions include maintaining a healthy weight, avoiding late-night meals, elevating the head of the bed, limiting alcohol and caffeine, and identifying individual trigger foods through an elimination approach.

Exploring PPI Alternatives at Cured Pharmacy

Cured Pharmacy offers a range of acid-reflux treatments including Esomeprazole 20mg from £9.99, Lansoprazole Capsules from £9.99, and Pantoprazole Gastro Resistant Tablets from £9.99. All prescription medications require a free online consultation with our UK prescribers, who will review your treatment history and determine the most appropriate therapy based on your individual clinical profile.

How to Stop Omeprazole Safely Without Rebound Symptoms

Abruptly discontinuing omeprazole after long-term use frequently triggers rebound acid hypersecretion, a physiological response where the stomach produces excessive acid for several weeks after PPI withdrawal [7]. This can cause severe heartburn, regurgitation, and dyspepsia that may be more intense than the original symptoms, leading many patients to resume treatment unnecessarily.

A gradual tapering strategy is generally more successful than sudden cessation. This might involve reducing from 20mg daily to 10mg daily for two to four weeks, then switching to on-demand dosing or transitioning to an H2-receptor antagonist before complete discontinuation [7]. Some patients benefit from taking the PPI every other day during the taper phase.

During the withdrawal period, intensifying lifestyle modifications and using alginate-based products like Gaviscon for breakthrough symptoms can help manage rebound effects without resuming full PPI therapy. Most patients find that rebound symptoms resolve within two to eight weeks of complete cessation, though this varies considerably based on treatment duration and individual factors.

Scientific References

1. Strand, D. S., Kim, D., & Peura, D. A. (2017). 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut and Liver, 11(1), 27–37. https://doi.org/10.5009/gnl15502 [accessed 13 August 2026]
2. Freedberg, D. E., Kim, L. S., & Yang, Y. X. (2017). The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice. Gastroenterology, 152(4), 706–715. https://doi.org/10.1053/j.gastro.2017.01.031 [accessed 13 August 2026]
3. Vaezi, M. F., Yang, Y. X., & Howden, C. W. (2017). Complications of Proton Pump Inhibitor Therapy. Gastroenterology, 153(1), 35–48. https://doi.org/10.1053/j.gastro.2017.04.047 [accessed 13 August 2026]
4. Ngamruengphong, S., Leontiadis, G. I., Radhi, S., Dentino, A., & Nugent, K. (2011). Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies. American Journal of Gastroenterology, 106(7), 1209–1218. https://doi.org/10.1038/ajg.2011.113 [accessed 13 August 2026]
5. Lam, J. R., Schneider, J. L., Zhao, W., & Corley, D. A. (2013). Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency. JAMA, 310(22), 2435–2442. https://doi.org/10.1001/jama.2013.280490 [accessed 13 August 2026]
6. Xie, Y., Bowe, B., Li, T., Xian, H., Balasubramanian, S., & Al-Aly, Z. (2016). Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. Journal of the American Society of Nephrology, 27(10), 3153–3163. https://doi.org/10.1681/ASN.2015121377 [accessed 13 August 2026]
7. Reimer, C., Søndergaard, B., Hilsted, L., & Bytzer, P. (2009). Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy. Gastroenterology, 137(1), 80–87. https://doi.org/10.1053/j.gastro.2009.03.045 [accessed 13 August 2026]
8. Imfeld, P., Bodmer, M., Jick, S. S., & Meier, C. R. (2018). Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis. Drug Safety, 41(12), 1387–1396. https://doi.org/10.1007/s40264-018-0704-9 [accessed 13 August 2026]
9. NHS. (2026). Heartburn and acid reflux. https://www.nhs.uk/conditions/heartburn-and-acid-reflux/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or making changes to your current treatment regimen.